NLRP3 and necrotizing enterocolitis: Excessive NLRP3 inflammasome activation and IL-1β production is capable of disrupting the intestinal mucosal barrier, directing neutrophils to injured site and promoting macrophage activation, representing promising therapeutic targets for NEC intestinal injury [23].